T-VEC Not Top Banana, but Still in the Pudding

Amgen Inc. didn't exactly take the blue ribbon for data on oncolytic immunotherapy talimogene laherparepvec, better known as T-VEC, at ASCO 2013. However, a first pass at key overall survival (OS) findings suggested the compound may still be in the mix for melanoma, though perhaps with a lower anticipated market opportunity than currently marketed Yervoy (ipilimumab, Bristol-Myers Squibb Co.) and highly anticipated PD-1 therapies.